SynthesisFrontiers in pharmacology2025

Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis.

Xiaojian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.